Head of Kexing Vaccine

The person in charge of Kexing vaccine is Cao, who has passed away.

Kexing Bio is the first China vaccine company to be listed in the United States (Nasdaq Global Select Market). SAIF, the largest shareholder, holds 65,438+05.07%, Yin Weidong, the second largest shareholder, holds 8.89%, and CDH Utopia and Vivo Capital hold 8.25% respectively. Kexing Bio owns Beijing Kexing Bio, Beijing Kexing Zhongwei, Kexing (Dalian) Vaccine and Beijing Kexing Zhong Yi Bio through its wholly-owned subsidiary Kexing Holdings (HK), and invests in Zhejiang Jinyi Shi Sheng Bio-engineering Co., Ltd.

The money earned by Kexing Bio mainly depends on Kexing Zhongwei. Before the "cash cow" of Kexing Zhongwei, Beijing Kexing Bio, Kexing (Dalian) Vaccine and Beijing Kexing Zhong Yi Bio were much weaker in making money. Sino Biopharmaceutical Limited's financial report revealed the secret.

Has the Kexing vaccine been stopped?

No, China Foreign Ministry spokesperson Hua Chunying once said that Bloomberg published a report entitled "China Kexing Vaccine is Very Effective in Real World Research". According to the article, a follow-up survey of domestic medical workers vaccinated with Kexing vaccine found that all the vaccinated people were free from death, 96% from hospitalization and 94% from infection.

The China Municipal Government has always given priority to the safety and effectiveness of the new pneumonia vaccine, and China vaccine research and development enterprises have also been promoting vaccine research and development in strict accordance with scientific laws and regulatory requirements. I also hope that the media can report the current epidemic situation and vaccine objectively and fairly from the facts.

Refer to Beijing Kexing Biological Products Co., Ltd. for the above contents.